Please assess the completion status of the following clinical trial:

Trial Title: Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained and informed consent form (ICF) signed.~* Female, aged 18-45 years.~* Sexually active with greater than or equal to 4 episodes of sex with a male partner during the past month.~* Human immunodeficiency virus (HIV)-seronegative on both HIV tests in parallel screening.~* Presence of bacterial vaginosis (BV) and/or vulvovaginal candidiasis (VVC) and/or T. vaginalis infection at screening:~  1. BV: Microscopic criteria (Nugent's score greater than or equal to 7)~ 2. VVC: Fungal elements (pseudohyphae, blastoconidia, or both) on vaginal saline wet mount plus a positive culture showing yeast on Sabouraud's agar.~ 3. T. vaginalis infection: Identification of motile trichomonads on vaginal saline wet preparation.~* Able and willing to comply with study visit schedule and procedures during the 12-month period of follow-up.~* Able and willing to abstain from sex or to use non-latex condoms (provided) for 24 hours following insertion of each vaginal suppository.~* Willing to abstain from alcohol during, and for 48 hours after, treatment.~* Plan to remain in study area for the next year.~* Agree to not participate in other research studies involving drugs, medical devices, or vaginal products for the duration of study.~Exclusion Criteria:~* Currently pregnant (positive urine Beta-Human Chorionic Gonadotropin (hCG) or planning to conceive during the next 12 months (by self-report).~* Currently breastfeeding.~* Within first 3 months post-partum.~* Current menstruation - women who are currently menstruating may be enrolled following the completion of menses.~* History of 4 or more episodes of treatment for any vaginal infection in the past 12 months. This would be a cumulative total, including any treatment for bacterial vaginosis (BV) and/or vulvovaginal candidiasis (VVC) and/or Trichomonas vaginalis (TV) and/or syndromic.~* History of medical condition that would contraindicate use of the study product~  1. Porphyria~ 2. Epilepsy~ 3. Serious liver disease or signs and symptoms consistent with serious liver disease including jaundice, ascites, esophageal varices, encephalopathy, and bleeding disorders.~ 4. Renal failure~* History of adverse reaction to the study medications (intravaginal metronidazole or miconazole).~* Current use of medication that may interact with the study drug (due to vaginal absorption of study drug)~  1. Warfarin~ 2. Phenytoin~ 3. Phenobarbital~ 4. Disulfiram~ 5. Cimetidine~ 6. Lithium~ 7. Astemizole~ 8. Terfenadine~* Current use of oral or intravaginal antifungal medication.~* Current use of oral or intravaginal metronidazole, tinidazole, or clindamycin.~* Current use of latex diaphragm.~* As determined by the investigator, a medical condition or situation exists such that study participation would not be advisable.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Intravaginal metronidazole 750 mg plus miconazole 200 mg (co-formulated suppositories) nightly for 5 consecutive nights each month; 117 Subjects.
- Arm 2 (Type: PLACEBO_COMPARATOR): Placebo suppositories nightly for five consecutive nights each month; 117 Subjects.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete